[HTML][HTML] KRAS mutations in solid tumors: characteristics, current therapeutic strategy, and potential treatment exploration
Y Yang, H Zhang, S Huang, Q Chu - Journal of Clinical Medicine, 2023 - mdpi.com
Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid
tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for …
tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for …
[HTML][HTML] Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and …
X Lu, Y Li, Y Li, X Zhang, J Shi, H Feng, Z Yu, Y Gao - BMC cancer, 2023 - Springer
Background RAS mutations affect prognosis in patients with metastatic colorectal cancer
(mCRC) and have been identified as strong negative predictive markers for anti-epidermal …
(mCRC) and have been identified as strong negative predictive markers for anti-epidermal …
[HTML][HTML] Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study
J Duan, L Zhu, Y Shi, W Wang, T Wang, T Ning… - BMC cancer, 2024 - Springer
Background There are various recommendations for third-line treatment in mCRC, however,
there is no consensus on who is more suitable for particular strategy. Chemotherapy re-use …
there is no consensus on who is more suitable for particular strategy. Chemotherapy re-use …
Third-line treatment patterns and clinical outcomes for metastatic colorectal cancer: a retrospective real-world study
T Deng, J Duan, M Bai, L Zhang, H Li… - … in Chronic Disease, 2023 - journals.sagepub.com
Background: There are multiple recommendations on the third-line therapy of metastatic
colorectal cancer (mCRC); however, no consensus has been reached. Objectives: This …
colorectal cancer (mCRC); however, no consensus has been reached. Objectives: This …
PIK3CA Mutations as a Prognostic Factor in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy
J Byun, NJ Park, G Yoon, MK Kang, HJ Kim… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: PIK3CA mediates various cellular processes, such as transformation,
tumor initiation and proliferation, and resistance to apoptosis. This study was conducted to …
tumor initiation and proliferation, and resistance to apoptosis. This study was conducted to …